Enanta Pharmaceuticals's top three insider shareholders as of May 30, 2026 are Jay R. Luly (President And Ceo, 871.87K shares), Yat Sun Or (Chief Scientific Officer, 374.85K shares), Paul J Mellett (Chief Fin. Admin Officer, 95.88K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Paul J Mellett | Chief Fin. Admin Officer | 95,884 | 0 | 14 Feb, 2025 |
| Jay R. Luly | President And Ceo | 871,871 | 0 | 13 Feb, 2026 |
| Yat Sun Or | Chief Scientific Officer | 374,854 | 0 | 13 Feb, 2026 |
| Terry Vance | - | 5,800 | 0 | 15 Dec, 2023 |
| Nathaniel S. Gardiner | Chief Legal Officer | 75,688 | 0 | 27 Feb, 2024 |
| Nathalie Adda | Sr. Vp Chief Medical Officer | 34,982 | 0 | 05 Apr, 2022 |
| Matthew Paul Kowalsky | Chief Legal Officer | 3,591 | 0 | 13 Feb, 2026 |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 33,925 | 0 | 13 Feb, 2026 |
| Brendan Luu | Chief Business Officer | 41,634 | 0 | 13 Feb, 2026 |
| Scott T. Rottinghaus | Chief Medical Officer | 25,254 | 0 | 13 Feb, 2026 |
| Harry R. Iii Trout | - | 16,348 | 0 | 05 Dec, 2025 |
| Kathleen S. Capps | - | 8,377 | 0 | 05 Dec, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 11 Mar, 2026 | Terry Vance | Stock Option (right to buy) | A | 20,000 | $0.00 | 20,000 | D | A |
| 11 Mar, 2026 | Lesley Russell | Stock Option (right to buy) | A | 20,000 | $0.00 | 20,000 | D | A |
| 11 Mar, 2026 | Terry Vance | Stock Option (right to buy) | A | 20,000 | $0.00 | 20,000 | D | A |
| 11 Mar, 2026 | Yujiro S Hata | Stock Option (right to buy) | A | 20,000 | $0.00 | 20,000 | D | A |
| 11 Mar, 2026 | Bruce L A Carter | Stock Option (right to buy) | A | 20,000 | $0.00 | 20,000 | D | A |
| 12 Feb, 2026 | Tara Lynn Kieffer | Common Stock | A | 1,575 | $0.00 | 32,195 | D | A |
| 12 Feb, 2026 | Matthew Paul Kowalsky | Common Stock | A | 1,318 | $0.00 | 1,318 | D | A |
| 12 Feb, 2026 | Scott T. Rottinghaus | Common Stock | A | 1,650 | $0.00 | 23,442 | D | A |
| 12 Feb, 2026 | Jay R. Luly | Common Stock | A | 4,800 | $0.00 | 862,826 | D | A |
| 12 Feb, 2026 | Brendan Luu | Common Stock | A | 1,575 | $0.00 | 39,904 | D | A |
| 12 Feb, 2026 | Yat Sun Or | Common Stock | A | 1,650 | $0.00 | 373,042 | D | A |
| 12 Feb, 2026 | Scott T. Rottinghaus | Common Stock | A | 1,650 | $0.00 | 23,442 | D | A |
| 12 Feb, 2026 | Brendan Luu | Common Stock | A | 1,575 | $0.00 | 39,904 | D | A |
| 12 Feb, 2026 | Tara Lynn Kieffer | Common Stock | A | 1,575 | $0.00 | 32,195 | D | A |
| 12 Feb, 2026 | Yat Sun Or | Common Stock | A | 1,650 | $0.00 | 373,042 | D | A |
| 12 Feb, 2026 | Jay R. Luly | Common Stock | A | 4,800 | $0.00 | 862,826 | D | A |
| 12 Feb, 2026 | Yat Sun Or | Common Stock | A | 5,225 | $0.00 | 378,267 | D | A |
| 12 Feb, 2026 | Tara Lynn Kieffer | Common Stock | A | 4,987 | $0.00 | 37,182 | D | A |
| 12 Feb, 2026 | Jay R. Luly | Common Stock | A | 15,200 | $0.00 | 878,026 | D | A |
| 12 Feb, 2026 | Yat Sun Or | Common Stock | A | 5,225 | $0.00 | 378,267 | D | A |